Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen plus PRP in High Risk Proliferative Diabetic Retinopathy
NCT01281098Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2010
- Primary completion
- Oct 2012
- Countries
- 1
- Sponsor
- AIBILI
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Drugs
- pegaptanib sodium
- Conditions
- proliferative diabetic retinopathy (PDR)
01
Overview
Phase 2, randomised, open-label trial of pegaptanib sodium in proliferative diabetic retinopathy (PDR), sponsored by AIBILI. Started Mar 2010; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Adult patients with high-risk proliferative diabetic retinopathy, BCVA > 20/320, and no prior panretinal photocoagulation or recent anti-VEGF therapy.
04
Registry description
To evaluate the safety and determine the efficacy of PRP monotherapy or combination therapy (pegaptanib 0.3 mg plus PRP) in patients with Type I or Type II diabetes mellitus and with high risk proliferative diabetic retinopathy.
Beyond the preview
Go deeper on NCT01281098.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281098.